|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goyal L, Qadan M and Zhu AX: Another
treatment option for advanced hepatocellular carcinoma with portal
vein thrombosis in China. JAMA Oncol. 5:938–939. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Medavaram S and Zhang Y: Emerging
therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol.
7:172018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ikeda K: Recent advances in medical
management of hepatocellular carcinoma. Hepatol Res. 49:14–32.
2019. View Article : Google Scholar
|
|
7
|
Zhang Q, Wang S, Qiao R, Whittaker MR,
Quinn JF, Davis TP and Li H: Recent advances in magnetic
nanoparticle-based molecular probes for hepatocellular carcinoma
diagnosis and therapy. Curr Pharm Des. 24:2432–2437. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sartorius K, Makarova J, Sartorius B, An
P, Winkler C, Chuturgoon A and Kramvis A: The regulatory role of
microRNA in hepatitis-B virus-associated hepatocellular carcinoma
(HBV-HCC) pathogenesis. Cells. 8:15042019. View Article : Google Scholar
|
|
9
|
Zakharia K, Luther CA, Alsabbak H and
Roberts LR: Hepatocellular carcinoma: Epidemiology, pathogenesis
and surveillance-implications for sub-Saharan Africa. S Afr Med J.
108:35–40. 2018.PubMed/NCBI
|
|
10
|
Hu G, Niu F, Humburg BA, Liao K, Bendi S,
Callen S, Fox HS and Buch S: Molecular mechanisms of long noncoding
RNAs and their role in disease pathogenesis. Oncotarget.
9:18648–18663. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Egranov SD, Yang L and Lin C:
Molecular mechanisms of long noncoding RNAs-mediated cancer
metastasis. Genes Chromosomes Cancer. 58:200–207. 2019. View Article : Google Scholar
|
|
12
|
Liz J and Esteller M: lncRNAs and
microRNAs with a role in cancer development. Biochim Biophys Acta.
1859:169–176. 2016. View Article : Google Scholar
|
|
13
|
Li W, He Y, Chen W, Man W, Fu Q, Tan H,
Guo H, Zhou J and Yang P: Knockdown of LINC00467 contributed to
Axitinib sensitivity in hepatocellular carcinoma through
miR-509-3p/PDGFRA axis. Gene Ther. Mar 27–2020.Epub ahead of print.
View Article : Google Scholar
|
|
14
|
Lu Z, Yu Y, Ding X, Jin D, Wang G, Zhou Y,
Zhu Y, Na L, He Y and Wang Q: LncRNA FLJ33360 accelerates the
metastasis in hepatocellular carcinoma by targeting miRNA-140/MMP9
axis. Am J Transl Res. 12:583–591. 2020.PubMed/NCBI
|
|
15
|
Liu C, Zhang M, Zhao J, Zhu X, Zhu L, Yan
M, Zhang X and Zhang R: LncRNA FOXD3-AS1 mediates AKT pathway to
promote growth and invasion in hepatocellular carcinoma through
regulating RICTOR. Cancer Biother Radiopharm. 35:292–300. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen X, Tang FR, Arfuso F, Cai WQ, Ma Z,
Yang J and Sethi G: The emerging role of long non-coding RNAs in
the metastasis of hepatocellular carcinoma. Biomolecules.
10:662019. View Article : Google Scholar
|
|
17
|
Xu X, Tao Y, Shan L, Chen R, Jiang H, Qian
Z, Cai F, Ma L and Yu Y: The role of microRNAs in hepatocellular
carcinoma. J Cancer. 9:3557–3569. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang T, Yang Z, Kusumanchi P, Han S and
Liangpunsakul S: Critical role of microRNA-21 in the pathogenesis
of liver diseases. Front Med (Lausanne). 7:72020. View Article : Google Scholar
|
|
20
|
Weidle UH, Schmid D, Birzele F and
Brinkmann U: MicroRNAs involved in metastasis of hepatocellular
carcinoma: Target candidates, functionality and efficacy in animal
models and prognostic relevance. Cancer Genomics Proteomics.
17:1–21. 2020. View Article : Google Scholar :
|
|
21
|
Pratama MY, Pascut D, Massi MN and
Tiribelli C: The role of microRNA in the resistance to treatment of
hepatocellular carcinoma. Ann Transl Med. 7:5772019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li D, Wang T, Sun FF, Feng JQ, Peng JJ, Li
H, Wang C, Wang D, Liu Y, Bai YD, et al: MicroRNA-375 represses
tumor angiogenesis and reverses resistance to sorafenib in
hepatocarcinoma. Cancer Gene Ther. July 3–2020.Epub ahead of print.
View Article : Google Scholar
|
|
23
|
Xu Q and Liu K: MiR-369-3p inhibits
tumorigenesis of hepatocellular carcinoma by binding to PAX6. J
Biol Regul Homeost Agents. Jun 30–2020.Epub ahead of print.
|
|
24
|
Wang J, Li J, Chen L, Fan Z and Cheng J:
MicroRNA-499 suppresses the growth of hepatocellular carcinoma by
downregulating astrocyte elevated gene-1. Technol Cancer Res Treat.
19:15330338209202532020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song X, Cao G, Jing L, Lin S, Wang X,
Zhang J, Wang M, Liu W and Lv C: Analysing the relationship between
lncRNA and protein-coding gene and the role of lncRNA as ceRNA in
pulmonary fibrosis. J Cell Mol Med. 18:991–1003. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
27
|
Shi SH, Jiang J, Zhang W, Sun L, Li XJ, Li
C, Ge QD and Zhuang ZG: A novel lncRNA HOXC-AS3 acts as a
miR-3922-5p sponge to promote breast cancer metastasis. Cancer
Invest. 38:1–12. 2020. View Article : Google Scholar
|
|
28
|
Tian Y, Xia S, Ma M and Zuo Y: LINC00096
promotes the proliferation and invasion by sponging miR-383-5p and
regulating RBM3 expression in triple-negative breast cancer. Onco
Targets Ther. 12:10569–10578. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang GY, Zhang AQ, Wang J, Li CH, Wang XQ,
Pan K, Zhou C and Dong JH: Hepatoma-derived growth factor promotes
growth and metastasis of hepatocellular carcinoma cells. Cell
Biochem Funct. 34:274–285. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Enomoto H, Nakamura H, Liu W, Iwata Y,
Nishikawa H, Takata R, Yoh K, Hasegawa K, Ishii A, Takashima T, et
al: Down-regulation of HDGF inhibits the growth of hepatocellular
carcinoma cells in vitro and in vivo. Anticancer Res. 35:6475–6479.
2015.PubMed/NCBI
|
|
31
|
Enomoto H, Nakamura H, Liu W and
Nishiguchi S: Hepatoma-derived growth factor: Its possible
involvement in the progression of hepatocellular carcinoma. Int J
Mol Sci. 16:14086–14097. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Agostini M, Ganini C, Candi E and Melino
G: The role of noncoding RNAs in epithelial cancer. Cell Death
Discov. 6:132020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsagakis I, Douka K, Birds I and Aspden
JL: Long non-coding RNAs in development and disease: Conservation
to mechanisms. J Pathol. 250:480–495. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu Z, Wei ZH and Chen SH: LncUBE2R2-AS1
acts as a microRNA sponge of miR-302b to promote HCC progression
via activation EGFR-PI3K-AKT signaling pathway. Cell Cycle. Aug
23–2020.Epub ahead of print. View Article : Google Scholar
|
|
35
|
Xie SC, Zhang JQ, Jiang XL, Hua YY, Xie
SW, Qin YA and Yang YJ: LncRNA CRNDE facilitates epigenetic
suppression of CELF2 and LATS2 to promote proliferation, migration
and chemoresistance in hepatocellular carcinoma. Cell Death Dis.
11:6762020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li Y, Guo D, Lu G, Mohiuddin Chowdhury
ATM, Zhang D, Ren M, Chen Y, Wang R and He S: LncRNA SNAI3-AS1
promotes PEG10-mediated proliferation and metastasis via decoying
of miR-27a-3p and miR-34a-5p in hepatocellular carcinoma. Cell
Death Dis. 11:6852020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shang R, Wang M, Dai B, Du J, Wang J, Liu
Z, Qu S, Yang X, Liu J, Xia C, et al: Long noncoding RNA SLC2A1-AS1
regulates aerobic glycolysis and progression in hepatocellular
carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway. Mol Oncol.
14:1381–1396. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chi Y, Gong Z, Xin H, Wang Z and Liu Z:
Long noncoding RNA lncARSR promotes nonalcoholic fatty liver
disease and hepatocellular carcinoma by promoting YAP1 and
activating the IRS2/AKT pathway. J Transl Med. 18:1262020.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mao LH, Chen SY, Li XQ, Xu F, Lei J, Wang
QL, Luo LY, Cao HY, Ge X, Ran T, et al: LncRNA-LALR1 upregulates
small nucleolar RNA SNORD72 to promote growth and invasion of
hepatocellular carcinoma. Aging (Albany NY). 12:4527–4546. 2020.
View Article : Google Scholar
|
|
40
|
Jin J, Xu H, Li W, Xu X, Liu H and Wei F:
LINC00346 acts as a competing endogenous RNA regulating development
of hepatocellular carcinoma via modulating CDK1/CCNB1 axis. Front
Bioeng Biotechnol. 8:542020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen S, Wang G, Tao K, Cai K, Wu K, Ye L,
Bai J, Yin Y, Wang J, Shuai X, et al: Long noncoding RNA
metastasis-associated lung adenocarcinoma transcript 1 cooperates
with enhancer of zeste homolog 2 to promote hepatocellular
carcinoma development by modulating the microRNA-22/Snail family
transcriptional repressor 1 axis. Cancer Sci. 111:1582–1595. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao JT, Chi BJ, Sun Y, Chi NN, Zhang XM,
Sun JB, Chen Y and Xia Y: LINC00174 is an oncogenic lncRNA of
hepatocellular carcinoma and regulates miR-320/S100A10 axis. Cell
Biochem Funct. Mar 3–2020.Epub ahead of print.
|
|
43
|
Xiao JR, Wang K, Liu Y, Li ZW, Zhou YJ,
Wang HZ, Lu JY, Cheng SS and Wei S: Exploring of a prognostic long
non-coding RNA signature of hepatocellular carcinoma by using
public database. Zhonghua Liu Xing Bing Xue Za Zhi. 40:805–809.
2019.In Chinese. PubMed/NCBI
|
|
44
|
Ma Y, Zhang J, Wen L and Lin A:
Membrane-lipid associated lncRNA: A new regulator in cancer
signaling. Cancer Lett. 419:27–29. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Niu ZS, Wang WH, Dong XN and Tian LM: Role
of long noncoding RNA-mediated competing endogenous RNA regulatory
network in hepatocellular carcinoma. World J Gastroenterol.
26:4240–4260. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ye Y, Shen A and Liu A: Long non-coding
RNA H19 and cancer: A competing endogenous RNA. Bull Cancer.
106:1152–1159. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Niu YC, Tong J, Shi XF and Zhang T:
MicroRNA-654-3p enhances cisplatin sensitivity by targeting QPRT
and inhibiting the PI3K/AKT signaling pathway in ovarian cancer
cells. Exp Ther Med. 20:1467–1479. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Deng G, Mou T, He J, Chen D, Lv D, Liu H,
Yu J, Wang S and Li G: Circular RNA circRHOBTB3 acts as a sponge
for miR-654-3p inhibiting gastric cancer growth. J Exp Clin Cancer
Res. 39:12020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Geraldo MV, Nakaya HI and Kimura ET:
Down-regulation of 14q32-encoded miRNAs and tumor suppressor role
for miR-654-3p in papillary thyroid cancer. Oncotarget.
8:9597–9607. 2017. View Article : Google Scholar :
|
|
50
|
Zhou X, Li J, Teng J, Liu Y, Zhang D, Liu
L and Zhang W: Long noncoding RNA BSN-AS2 induced by E2F1 promotes
spinal osteosarcoma progression by targeting miR-654-3p/SYTL2 axis.
Cancer Cell Int. 20:1332020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang J, Chen S, Dou W, Xie R and Gao J:
miR-654-3p predicts the prognosis of hepatocellular carcinoma and
inhibits the proliferation, migration, and invasion of cancer
cells. Cancer Biomark. 28:73–79. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang JS, Chao CC, Su TL, Yeh SH, Chen DS,
Chen CT, Chen PJ and Jou YS: Diverse cellular transformation
capability of overexpressed genes in human hepatocellular
carcinoma. Biochem Biophys Res Commun. 315:950–958. 2004.
View Article : Google Scholar : PubMed/NCBI
|
